Thank You Vineet Erasala, COO of Genetesis for spending some time with our Braves, sharing your story & how a passion for engineering & medicine led you to this incredible innovation! What started with a question led him to become a pioneer in medtech! Indian Hill Schools

We’re excited to announce the formal publication of results from the MAGNETO trial! They highlight resting MCG as a rapid, radiation-free alternative to standard of care stress testing for diagnosing myocardial ischemia in acute chest pain patients. shorturl.at/dALOX

We've been accepted into the ARPA-H Investor Catalyst Hub as a spoke member. This comes at a time when ARPA-H and many other key players in healthcare are doubling down on the importance of addressing key deficiencies in how women receive care. genetesis.com/press-releases…

Why Mark Cuban And Others Are Betting $40 Million On This Under 30 Start Up trib.al/BAsHkRQ

Why Mark Cuban And Others Are Betting $40 Million On This Under 30 Start Up trib.al/Z1vRrPA

A novel case series in American Heart Journal Plus exploring the value of MCG for myocarditis assessment. Congrats Bettina Heidecker and team on this very exciting new paper! sciencedirect.com/science/articl…

🚀 Exciting News Alert! 🚀 Mark Cuban and other savvy investors are putting their money where it matters, betting $40 million on this under-30 start-up! We can't help but agree, as we're proud to have Genetesis as a part of our portfolio. forbes.com/sites/zoyahasa…

We're thrilled to announce the launch of our groundbreaking clinical trial, MICRO2, which aims to validate early evidence demonstrating MCG’s ability to aid in the noninvasive diagnosis of Coronary Microvascular Dysfunction. genetesis.com/press-releases…

“Our explorations thus far into CMD are a symbol of our commitment to demonstrating MCG’s utility across the entire spectrum of ischemic heart disease….” -Dr. Robert Takla who shares more here: genetesis.com/press-releases…

Yet another CardioFlux paper out today in AHJPlus! This one demonstrates the promise of MCG to detect physiological changes just hours after revascularization: sciencedirect.com/science/articl…

Amazing and thankful to see so many incredible investigators partnering with us on our pivotal #MICRO2 trial Genetesis cc: Cleveland Clinic, Saint Luke's Ascension St. John And many more partners to be featured soon!

📷📷Yet another paper out on CardioFlux, this time showcasing the first ever national cost savings analysis potential of MCG! This paper is a collab between researchers at Brigham and Women's Hospital , Cleveland Clinic and Ascension St. John Read more here: sciencedirect.com/science/articl…

“A strategy using Magnetocardiography as an initial screening test before conventional cardiac diagnostics could yield significant financial, operational and safety benefits” - Baugh et al. 2024

Exciting work from Christopher Baugh MD and colleagues!

In 2014, Forbes highlighted that the U.S. wastes over $500 million/yr on inappropriate stress tests: forbes.com/sites/larryhus… Now, 10 years later Christopher Baugh MD shows how #magnetocardiography can completely reverse the damage (and improve quality while doing it!). Exciting!

Congratulations to #MasonOH partner @GenetesisINC and their MICRO2 study team at Mayo Clinic on enrolling their first MICRO2 patient! Their advancements in cardiology research have global impact, and they’re being made right here in our community. #MasonLovesBio #TechHub

CardioFlux is now approved in Canada 🇨🇦 It is indicated for the diagnosis of #ischemia, and this newly granted medical device license is a landmark victory for #magnetocardiography, as this is the FIRST clinical approval of an MCG device, ever. prnewswire.com/news-releases/…

We are thrilled to announce that Health Canada has officially approved CardioFlux MCG for the diagnosis of myocardial ischemia! 🎉 This milestone marks the first approval of an MCG device in Canadian regulatory history. genetesis.com/press-releases…

Raptor Group portfolio company Genetesis has announced that Health Canada has officially approved CardioFlux MCG for the diagnosis of myocardial ischemia. This marks the first approval of an MCG device in Canadian regulatory history 👋